NO20044272L - Legemiddel for behandling og/eller forebyggelse av kronisk avstotning - Google Patents
Legemiddel for behandling og/eller forebyggelse av kronisk avstotningInfo
- Publication number
- NO20044272L NO20044272L NO20044272A NO20044272A NO20044272L NO 20044272 L NO20044272 L NO 20044272L NO 20044272 A NO20044272 A NO 20044272A NO 20044272 A NO20044272 A NO 20044272A NO 20044272 L NO20044272 L NO 20044272L
- Authority
- NO
- Norway
- Prior art keywords
- medication
- prevention
- treatment
- chronic rejection
- rejection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37241902P | 2002-04-16 | 2002-04-16 | |
PCT/JP2003/004722 WO2003086391A1 (en) | 2002-04-16 | 2003-04-14 | New use |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20044272L true NO20044272L (no) | 2004-12-15 |
Family
ID=29250850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20044272A NO20044272L (no) | 2002-04-16 | 2004-10-08 | Legemiddel for behandling og/eller forebyggelse av kronisk avstotning |
Country Status (18)
Country | Link |
---|---|
US (2) | US20030232867A1 (de) |
EP (1) | EP1494669A1 (de) |
JP (1) | JP2005526107A (de) |
KR (1) | KR20040101381A (de) |
CN (1) | CN1646122A (de) |
AR (1) | AR039416A1 (de) |
AU (1) | AU2003223119A1 (de) |
BR (1) | BR0309427A (de) |
CA (1) | CA2481184A1 (de) |
IL (1) | IL164185A0 (de) |
MX (1) | MXPA04010170A (de) |
NO (1) | NO20044272L (de) |
NZ (1) | NZ535692A (de) |
PL (1) | PL372902A1 (de) |
RU (1) | RU2004133347A (de) |
TW (1) | TW200306825A (de) |
WO (1) | WO2003086391A1 (de) |
ZA (1) | ZA200407813B (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431085B1 (de) | 2009-04-22 | 2023-10-11 | AskAt Inc. | Selektive ep4-rezeptorantagonistensubstanz zur krebsbehandlung |
US10813917B2 (en) | 2009-12-11 | 2020-10-27 | Medregen, Llc | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
CN104603096A (zh) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
CA2873098A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
WO2013175344A2 (en) * | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
CN104603100A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗炎症性肠病的组合物和方法 |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2016110865A1 (en) | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
EP3212626B1 (de) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Drei-komponenten-salze des fumarsäuremonomethylesters mit piperazin und ethylendiamin zur behandlung von multipler sclerosis |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
US5519042A (en) * | 1994-01-13 | 1996-05-21 | Hoechst Aktiengesellschaft | Method of treating hyperproliferative vascular disease |
US5624946A (en) * | 1994-07-05 | 1997-04-29 | Williams; James | Use of leflunomide to control and reverse chronic allograft rejection |
DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
UA65587C2 (en) * | 1997-10-09 | 2004-04-15 | Baker Norton Pharma | Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus |
-
2003
- 2003-04-14 NZ NZ535692A patent/NZ535692A/en unknown
- 2003-04-14 MX MXPA04010170A patent/MXPA04010170A/es unknown
- 2003-04-14 BR BR0309427-8A patent/BR0309427A/pt not_active IP Right Cessation
- 2003-04-14 EP EP03719104A patent/EP1494669A1/de not_active Withdrawn
- 2003-04-14 PL PL03372902A patent/PL372902A1/xx not_active Application Discontinuation
- 2003-04-14 WO PCT/JP2003/004722 patent/WO2003086391A1/en not_active Application Discontinuation
- 2003-04-14 IL IL16418503A patent/IL164185A0/xx unknown
- 2003-04-14 CN CNA038084996A patent/CN1646122A/zh active Pending
- 2003-04-14 JP JP2003583410A patent/JP2005526107A/ja not_active Withdrawn
- 2003-04-14 RU RU2004133347/14A patent/RU2004133347A/ru not_active Application Discontinuation
- 2003-04-14 KR KR10-2004-7015621A patent/KR20040101381A/ko not_active Application Discontinuation
- 2003-04-14 AU AU2003223119A patent/AU2003223119A1/en not_active Abandoned
- 2003-04-14 CA CA002481184A patent/CA2481184A1/en not_active Abandoned
- 2003-04-15 AR ARP030101314A patent/AR039416A1/es not_active Application Discontinuation
- 2003-04-15 TW TW092108600A patent/TW200306825A/zh unknown
- 2003-04-16 US US10/414,150 patent/US20030232867A1/en not_active Abandoned
-
2004
- 2004-09-28 ZA ZA200407813A patent/ZA200407813B/xx unknown
- 2004-10-08 NO NO20044272A patent/NO20044272L/no not_active Application Discontinuation
-
2005
- 2005-12-28 US US11/319,178 patent/US20060211725A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030232867A1 (en) | 2003-12-18 |
AR039416A1 (es) | 2005-02-16 |
NZ535692A (en) | 2006-07-28 |
JP2005526107A (ja) | 2005-09-02 |
EP1494669A1 (de) | 2005-01-12 |
RU2004133347A (ru) | 2005-05-10 |
CN1646122A (zh) | 2005-07-27 |
TW200306825A (en) | 2003-12-01 |
KR20040101381A (ko) | 2004-12-02 |
WO2003086391A1 (en) | 2003-10-23 |
MXPA04010170A (es) | 2005-02-03 |
US20060211725A1 (en) | 2006-09-21 |
PL372902A1 (en) | 2005-08-08 |
BR0309427A (pt) | 2005-02-01 |
CA2481184A1 (en) | 2003-10-23 |
AU2003223119A1 (en) | 2003-10-27 |
ZA200407813B (en) | 2005-10-18 |
IL164185A0 (en) | 2005-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20044272L (no) | Legemiddel for behandling og/eller forebyggelse av kronisk avstotning | |
NO20052626D0 (no) | Middel for forhindring eller behandling av neuropati | |
DK1487541T3 (da) | Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme | |
NO20050569D0 (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
NO20054913D0 (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
NO20052009D0 (no) | Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom | |
NO20100477L (no) | Anvendelse av risendronat til fremstilling av medikamenter for behandling og prevensjon av osteoporose | |
DE60322507D1 (de) | Steuerbarer katheter oder dergleichen | |
DK1663978T3 (da) | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser | |
NO20031448L (no) | Fremgangsmåte for fremstilling av nanopartikler av paclitaxel og albumin | |
AU2003237367A8 (en) | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer | |
DK1773361T3 (da) | Sammensætning baseret på probiotiske bakterier og anvendelse deraf til forebyggelse og/eller behandling af respiratoriske sygdomme og/eller infektioner og til forbedring af en intestinale funktionalitet | |
LTC1765293I2 (lt) | Farmacinės kompozicijos vaistų pristatymui ir būklių gydymo arba prevencijos būdai naudojant tas kompozicijas | |
NO20034430L (no) | Tiohydantoiner og anvendelse derav for behandling av diatbetes | |
NO20043309L (no) | Legemiddelleveringssystemer for hindring og behandling av vaskulaere sykdommer som innbefatter rapamycin og derivater derav | |
EA200500098A1 (ru) | Лекарственное средство и способ лечения патологического синдрома | |
DK1534248T3 (da) | Lasofoxifentablet og dens overtræk | |
DK1638589T3 (da) | Kombinationsterapi med glatirameracetat og mitoxantron til behandling af multipel sklerose | |
IS8359A (is) | Vefjaverndandi frumuboðar til meðferðar og forvarnar á blóðeitrun og samloðunarmyndun | |
IS7348A (is) | N-pýrasínýl-fenýlsúlfónamíð og notkun þeirra til að meðhöndla flakkboðatengda sjúkdóma | |
NO20031806D0 (no) | Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati | |
NO20045554L (no) | Fremgangsmate for behandling av diabetes | |
DE60319400D1 (de) | Atemfähiges und mehrlagiges gewebe | |
DK1355668T3 (da) | Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom | |
NO20054346D0 (no) | Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0 |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |